• 1.摘要
  • 2.基本信息
  • 3.内容简介
  • 4.图书目录

原发性肝癌:挑战与展望

顾健人著书籍

《原发性肝癌:挑战与展望》中,在中国肝癌领域的领先专家意在与读者分享他们的新概念,实践和经验,从实验室到床上,从人口研究的个案调查,从分子搜索到临床实践,从早期的诊断和治疗。《原发性肝癌:挑战与展望》的目的是为在肝癌和其他癌症的免疫学,流行病学,分子遗传学,细胞生物学和原发性肝癌的临床肿瘤学领域的研究人员提供理论知识。

基本信息

  • 外文名

    Primary Liver Cancer:Challenges and Perspectives

  • 出版社

    浙江大学出版社

  • 作者

    顾健人

  • 开本

    16

  • 页数

    462页

内容简介

《原发性肝癌:挑战与展望》由浙江大学出版社出版。

图书目录

1 Concepts, Challenges and Perspectives in Cancer Research 1.1 Cancer is a Well-Organized Tissue, Constructing a Specified Cancer Microenvironment 1.1.1 Cancer Associated Stromal Cells 1.1.2 Extracellular Matrix in Tumor 1.1.3 Tumor Acidic Microenvironment 1.2 Heterogeneity of Cancer Cell Population and Cancer Stem Cell Hypothesis 1.2.1 Cancer Stem Cell ttypothesis 1.2.2 Arguments against Cancer Stem Cell Hypothesis 1.3 Cancer is a Systems Disease--A Disease of Systems Dysregulation, Characterized by Abnormal Growth of the Defmed Tissue or Organ 1.3.1 Systemic Regulatory Systems to Control the Host-Cell Homeostasis 1.4 Prospects and Implications References 2.1 The New Concept ofHepatic Carcinogenesis: Two Levels ofSystemic Dysregulation in the Development ofHepatocellular Carcinoma (HCC) 2.1.1Hypothesis ofTwo Levels ofSystemic Regulation 2.1.2 Evidence ofSystemic Dysregulation ofCancer Development and Progression 2.2 Non-NeuronaINeurotransmitters and Hepatocellular Carcinoma 2.2.1The Cholinergic System in the Development ofHepatocellular Carcinoma 2.2.2 The Adrenergic System and Hepatocarcinogenesis 2.2.3The Glutamatergic System in the Development of Hepatocellular Carcinoma 2.2.4 The GABAergic System in the Development of Hepatocellular Carcinoma 2.3Regulatory Effects ofCholinergic System on Immune Cells andHormone Receptors ofHCC Cells 2.4 Prospects Acknowledgements References 3 Genomics ofHepatocellular Carcinoma 3.1 MultistepHepatocarcinogenesis 3.2 Genetic Susceptibility to Hepatocarcinogenesis 3.3 Genetic Alterations in Hepatocarcinogenesis 3.3.1 ChromosomaIAbnormalities 3.3.2 Somatic Mutations 3.3.3 Single Nucleotide Polymorphis 3.4 Epigenetic Alterations in HCC 3.5 MicroRNA and Hepatocarcinogenesis 3.6 Expression Profiling of HCC 3.7 Signaling Pathways in HCC 3.7.1 Wnup-Catenin Pathway 3.7.2 Ras Signaling Pathway 3.7.3 PI3K/Akt/mTORPathway 3.7.4 DLCl/Rho/ROCK Pathway 3.8 Concluding Remarks and Perspective Acknowledgements References 4 Biomarkers ofHepatocellular Carcinoma 4.1Overview ofthe HCC Biomarker Discovery and Development 4.1.1 Development and Evaluation ofBiomarkers for Early Detection/Diagnosis of HCC 4.2 Biomarkers for Early Detection/Diagnosis ofHepatocellular Carcinoma 4.2.1 Alpha-Fetoprotein 4.2.2 Glypican-3 4.2.3 Des-Gamma-Carboxyprothromb 4.2.4 Golgi Phosphoprotein 2 4.2.5 Other Potential Biomarkers for Diagnosis of HCC 4.2.6Combination ofBiomarkers for Diagnosis of HCC 4.2.7 Integrated ""Omics"" Analysis in Searching Biomarkers for Early Detection of HCC 4.3 Biomarkers for Prognosis ofHepatocellular Carcinoma 4.3.1 Tumor-AssociatedAntigens 4.3.2 Cell Cycle-Related Biomarkers 4.3.3Telomerase 4.3.4 Oncogenes and Tumor Suppressor Genes 4.3.5Cellular Adhesion Molecules 4.3.6 Extracellular Matrix Degradation Proteinases 4.3.7Tumor Angiogenesis 4.3.8 Tumor Microenvironment 4.3.9 Combination ofBiomarkers for Prognosis of HCC 4.3.10 Integrated ""Omics"" Analysis in Searching Biomarkers for Prognosis of HCC 4.4 Biomarkers for Molecular Classification and Treatment Selection ofHCC 4.4.1 Biomarkers for Molecular Classification of HCC 4.4.2 Biomarkers for HCC Treatment Selectio 4.5 Outlook Acknowledgements References 5 Metabonomics of Hepatocellular Carcinoma 5.1 Analytical Strategy of Metabonomics 5.1.1Collection of Samples 5.1.2 Collection ofMetabonome Data 5.1.3 Multivariate Data Analysis 5.2 Applications ofMetabonomics in Liver Cancer Study 5.2.1Blood, Serum and Bile Metabolic Profiling ofLiver Cancer 5.2.2Urine Metabolic Profiling ofLiver Cancer 5.2.3 Metabonomic Study ofHepatitis B Induced Liver Cirrhosis and Hepatocellular Carcinoma 5.2.4Liver Cancer Investigation Based on Modified Nucleosides in B odyFluids Acknowledgements References 6SignaITransduction ofHepatocellular Carcinoma 6.1Overview ofthe Signal Transduction in HCC 6.2 p53 and Rb Signaling Pathways in HCC 6.2.1 p53 Signaling Pathway in HCC 6.2.2 Rb Signaling Pathway in HCC 6.3 Mitogen Activated Protein Kinases Pathway in HCC 6.3.1 Subfamilies ofMAPKs 6.3.2 Common Signaling Pathway ofMAPKs 6.3.3Physiological Functions ofMAPKs 6.3.4 Alterations ofMAPKs in HCC 6.3.5 Other Constitutions ofMAPKs Signaling and their Alterationsin HCC 6.4 Wnt/β-Catenin Pathway in HCC 6.4.1 Wnt/β-Catenin Signaling and its Regulation 6.4.2 Aberrant Activation ofWnt/β-Catenin Signaling in HCC 6.5 Transforming Growth Factor-β Signaling in HCC 6.5.1 TGF-β Signaling Pathway and its Regulation 6.5.2 TGF-β Signaling in Different Stages ofHCC 6.6 Nuclear Factor-κB Pathway in HCC 6.6.1 Complex NF-κB Signaling SyOtem 6.6.2 Contradictory Effects ofNF-κB Activation onHepatocarcinogenesis 6.7 PI3K/Akt/mTOR Pathway in HCC 6.7.1 PI3K/Akt/mTOR Signaling andits Regulation 6.7.2 PI3K/Akt/mTOR Signalingin HCC 6.8 Other Pathways Associated with HCC 6.8.1 The JAK/STAT Pathwayin HCC 6.8.2 Hedgehog Signaling Pathway 6.8.3 Notch Signaling Pathway 6.8.4Stem Cell Related Signaling Pathways in HCC 6.9Molecular Targets for Therapy in HCC 6.9.1 Growth Factors-MAPK Pathway-Based Strategies 6.9.2 NF-KB-basedStrategies 6.9.3 PI3K/Akt/mTORPathway-BasedStrategies 6.9.4Other Targets for Therapy in HCC Acknowledgements References 7 Cancer Stem Cells ofHepatocellular Carcinoma 7 .1Introduction 7.2 Cancer Stem CelIHypothesis 7.3Identification ofHCC Stem Cells with Potential Stem Cell Markers 7.3.1 CD133+,CD133+/CD44+Cells 7.3.2 EpCAM+Cells 7.3.3 CD90+ Cells 7.3.4 OV6+ Cells 7.4 SP Cells ofHepatocellular Carcinoma 7.5Challenges to Cancer Stem Cell Hypothesis 7.6Clinical Impacts and Perspectives 7.7Conclusions References …… 8 Immunology of Liver 9 Immunosuppresssioa and Immune Escape in Liver Cancer 10 Immunotherapy of Hepatocellular Carcinoma 11 Chemoprevention of Hepatic Cancer in Aflatoxin Endemic Areas 12 Metastasis of Hepatic Cancer 13 Integrated Treatment of Hepatic Cancer 14 Liver Transplantation for HepatoceUular Carcinoma Index